Cargando…
Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database
Amphetamine is a psychostimulant drug with a high risk of toxicity and death when misused. Abuse of amphetamines is associated with an altered organic profile, which includes omega fatty acids. Low omega fatty acid levels are linked to mental disorders. Using the Comparative Toxicogenomic Database (...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305267/ https://www.ncbi.nlm.nih.gov/pubmed/37375342 http://dx.doi.org/10.3390/molecules28124787 |
_version_ | 1785065693228564480 |
---|---|
author | Tumayhi, Murad Banji, David Khardali, Ibrahim Banji, Otilia J. F. Alshahrani, Saeed Alqahtani, Saad S. Muqri, Safiah Abdullah, Amal Sherwani, Wedad Attafi, Ibraheem |
author_facet | Tumayhi, Murad Banji, David Khardali, Ibrahim Banji, Otilia J. F. Alshahrani, Saeed Alqahtani, Saad S. Muqri, Safiah Abdullah, Amal Sherwani, Wedad Attafi, Ibraheem |
author_sort | Tumayhi, Murad |
collection | PubMed |
description | Amphetamine is a psychostimulant drug with a high risk of toxicity and death when misused. Abuse of amphetamines is associated with an altered organic profile, which includes omega fatty acids. Low omega fatty acid levels are linked to mental disorders. Using the Comparative Toxicogenomic Database (CTD), we investigated the chemical profile of the brain in amphetamine-related fatalities and the possibility of neurotoxicity. We classified amphetamine cases as low (0–0.5 g/mL), medium (>0.5 to 1.5 g/mL), and high (>1.5 g/mL), based on amphetamine levels in brain samples. All three groups shared 1-octadecene, 1-tridecene, 2,4-di-tert-butylphenol, arachidonic acid (AA), docosahexaenoic acid (DHA), eicosane, and oleylamide. We identified chemical–disease associations using the CTD tools and predicted an association between DHA, AA and curated conditions like autistic disorder, disorders related to cocaine, Alzheimer’s disease, and cognitive dysfunction. An amphetamine challenge may cause neurotoxicity in the human brain due to a decrease in omega-3 fatty acids and an increase in oxidative products. Therefore, in cases of amphetamine toxicity, a supplement therapy may be needed to prevent omega-3 fatty acid deficiency. |
format | Online Article Text |
id | pubmed-10305267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103052672023-06-29 Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database Tumayhi, Murad Banji, David Khardali, Ibrahim Banji, Otilia J. F. Alshahrani, Saeed Alqahtani, Saad S. Muqri, Safiah Abdullah, Amal Sherwani, Wedad Attafi, Ibraheem Molecules Communication Amphetamine is a psychostimulant drug with a high risk of toxicity and death when misused. Abuse of amphetamines is associated with an altered organic profile, which includes omega fatty acids. Low omega fatty acid levels are linked to mental disorders. Using the Comparative Toxicogenomic Database (CTD), we investigated the chemical profile of the brain in amphetamine-related fatalities and the possibility of neurotoxicity. We classified amphetamine cases as low (0–0.5 g/mL), medium (>0.5 to 1.5 g/mL), and high (>1.5 g/mL), based on amphetamine levels in brain samples. All three groups shared 1-octadecene, 1-tridecene, 2,4-di-tert-butylphenol, arachidonic acid (AA), docosahexaenoic acid (DHA), eicosane, and oleylamide. We identified chemical–disease associations using the CTD tools and predicted an association between DHA, AA and curated conditions like autistic disorder, disorders related to cocaine, Alzheimer’s disease, and cognitive dysfunction. An amphetamine challenge may cause neurotoxicity in the human brain due to a decrease in omega-3 fatty acids and an increase in oxidative products. Therefore, in cases of amphetamine toxicity, a supplement therapy may be needed to prevent omega-3 fatty acid deficiency. MDPI 2023-06-15 /pmc/articles/PMC10305267/ /pubmed/37375342 http://dx.doi.org/10.3390/molecules28124787 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Tumayhi, Murad Banji, David Khardali, Ibrahim Banji, Otilia J. F. Alshahrani, Saeed Alqahtani, Saad S. Muqri, Safiah Abdullah, Amal Sherwani, Wedad Attafi, Ibraheem Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title | Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title_full | Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title_fullStr | Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title_full_unstemmed | Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title_short | Amphetamine-Related Fatalities and Altered Brain Chemicals: A Preliminary Investigation Using the Comparative Toxicogenomic Database |
title_sort | amphetamine-related fatalities and altered brain chemicals: a preliminary investigation using the comparative toxicogenomic database |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10305267/ https://www.ncbi.nlm.nih.gov/pubmed/37375342 http://dx.doi.org/10.3390/molecules28124787 |
work_keys_str_mv | AT tumayhimurad amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT banjidavid amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT khardaliibrahim amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT banjiotiliajf amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT alshahranisaeed amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT alqahtanisaads amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT muqrisafiah amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT abdullahamal amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT sherwaniwedad amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase AT attafiibraheem amphetaminerelatedfatalitiesandalteredbrainchemicalsapreliminaryinvestigationusingthecomparativetoxicogenomicdatabase |